- Home
- AKAM vs BMRN Comparison
AKAM vs BMRN Comparison
Compare AKAM & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAM
- BMRN
- Stock Information
- Founded
- AKAM 1998
- BMRN 1996
- Country
- AKAM United States
- BMRN United States
- Employees
- AKAM N/A
- BMRN N/A
- Industry
- AKAM Business Services
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AKAM Consumer Discretionary
- BMRN Health Care
- Exchange
- AKAM Nasdaq
- BMRN Nasdaq
- Market Cap
- AKAM 11.4B
- BMRN 10.0B
- IPO Year
- AKAM 1999
- BMRN 1999
- Fundamental
- Price
- AKAM $72.76
- BMRN $51.34
- Analyst Decision
- AKAM Hold
- BMRN Buy
- Analyst Count
- AKAM 17
- BMRN 22
- Target Price
- AKAM $94.00
- BMRN $90.14
- AVG Volume (30 Days)
- AKAM 1.5M
- BMRN 2.7M
- Earning Date
- AKAM 11-06-2025
- BMRN 10-27-2025
- Dividend Yield
- AKAM N/A
- BMRN N/A
- EPS Growth
- AKAM N/A
- BMRN 59.53
- EPS
- AKAM 2.82
- BMRN 2.68
- Revenue
- AKAM $4,083,251,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- AKAM $6.69
- BMRN $13.35
- Revenue Next Year
- AKAM $5.12
- BMRN $9.18
- P/E Ratio
- AKAM $25.88
- BMRN $19.35
- Revenue Growth
- AKAM 3.98
- BMRN 12.39
- 52 Week Low
- AKAM $67.51
- BMRN $51.57
- 52 Week High
- AKAM $105.26
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- AKAM 40.10
- BMRN 38.03
- Support Level
- AKAM $74.21
- BMRN $52.26
- Resistance Level
- AKAM $76.16
- BMRN $56.80
- Average True Range (ATR)
- AKAM 1.50
- BMRN 1.63
- MACD
- AKAM -0.07
- BMRN -0.10
- Stochastic Oscillator
- AKAM 11.25
- BMRN 0.73
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.